Tapering Off Antidepressants

Inclusion Criteria:

• Currently taking an FDA-approved antidepressant for at least four weeks on the list ofapproved medications: SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine,paroxetine, sertraline, vilazodone or vortioxetine), SNRIs (desvenlafaxine,duloxetine, levomilnacipran, venlafaxine) and other classes (amitriptyline, bupropion,desipramine, doxepin, mirtazapine, nefazodone, nortriptyline, phenelzine, selegiline,or tranylcypromine). Clomipramine, a tricyclic antidepressant approved for thetreatment of OCD, will also be included, but will be classed as an SSRI for this studybecause inhibition of the serotonin transporter is its primary therapeutic mechanism.

• No longer wish to take the antidepressant medication they are currently prescribed,due to one of the following reasons: 1) ineffective for symptoms; 2) intolerable sideeffect; 3) improvement of their illness for sufficient duration that it is clinicallyappropriate to consider tapering the medication.

• Primary psychiatric diagnosis of major depressive disorder, an anxiety disorder, OCD,or PTSD.

• Ability to read and understand English language.

Exclusion Criteria:

• Has met criteria at any time during their life for a primary psychotic disorder (e.g.schizophrenia), or dementia.

• Meets criteria for DSM-5-defined substance use disorder within three months of thescreening visit.

• Currently taking two or more antidepressants.

• Presents with a clinically significant suicide risk, as assessed by a study physician.

• Presence of any unstable or central nervous system-related medical illness that wouldinterfere with cognition or participation.

• Women who are currently pregnant or lactating, or plan to become pregnant during thestudy.